Truist Financial Cuts Astrana Health (NASDAQ:ASTH) Price Target to $50.00

Astrana Health (NASDAQ:ASTH) had its price target decreased by equities research analysts at Truist Financial from $59.00 to $50.00 in a research note issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. Truist Financial’s price target indicates a potential upside of 69.61% from the company’s previous close.

A number of other equities analysts also recently commented on the stock. Robert W. Baird boosted their target price on shares of Astrana Health from $67.00 to $86.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Macquarie upgraded shares of Astrana Health to a “hold” rating in a report on Monday, December 16th. KeyCorp initiated coverage on Astrana Health in a research note on Friday, October 11th. They set a “sector weight” rating on the stock. TD Cowen initiated coverage on Astrana Health in a research note on Monday, October 14th. They set a “buy” rating and a $66.00 price target on the stock. Finally, BTIG Research boosted their price target on Astrana Health from $60.00 to $70.00 and gave the stock a “buy” rating in a research note on Thursday, October 3rd. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $63.67.

Astrana Health Stock Down 6.9 %

Shares of ASTH opened at $29.48 on Monday. The firm has a market capitalization of $1.66 billion, a P/E ratio of 22.68, a P/E/G ratio of 1.80 and a beta of 1.20. Astrana Health has a 12-month low of $29.35 and a 12-month high of $63.20. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.60. The firm has a fifty day moving average price of $39.55 and a 200-day moving average price of $47.00.

Astrana Health (NASDAQ:ASTH) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.33 earnings per share for the quarter, meeting the consensus estimate of $0.33. The firm had revenue of $478.71 million during the quarter, compared to the consensus estimate of $462.01 million. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. During the same period in the previous year, the company posted $0.47 earnings per share. Equities research analysts expect that Astrana Health will post 1.16 earnings per share for the current year.

Institutional Investors Weigh In On Astrana Health

Several hedge funds have recently bought and sold shares of the stock. Janus Henderson Group PLC acquired a new position in shares of Astrana Health during the 3rd quarter worth approximately $1,164,000. Royce & Associates LP acquired a new stake in shares of Astrana Health in the 3rd quarter worth $6,661,000. Amalgamated Bank acquired a new stake in shares of Astrana Health in the 3rd quarter worth $713,000. Principal Financial Group Inc. acquired a new stake in shares of Astrana Health in the 3rd quarter worth $13,383,000. Finally, Diamond Hill Capital Management Inc. acquired a new stake in shares of Astrana Health in the 3rd quarter worth $8,245,000. Hedge funds and other institutional investors own 52.77% of the company’s stock.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.